A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Resumen de la noticia
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Sigue las últimas noticias de medios fiables con resúmenes breves. Abre el enlace original para ver los detalles.